Enoblituzumab binds B7-H3 on target cells and engages NK cells via Fc-gamma receptor (CD16) to trigger antibody-dependent cellular cytotoxicity (perforin/granzyme); additional Fc-mediated effector functions (e.g., macrophage phagocytosis) may contribute.